Author

Murray D. Norris

Children's Cancer Institute AustraliaORCID 0000-0002-0632-4589Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Alvin KamiliiD· 2 shared Jamie I. FletcheriD· 2 shared Michelle HaberiD· 2 shared Toby N. TrahairiD· 2 shared Andrew J. GiffordiD· 1 shared Angela Fontaine-TitleyiD· 1 shared Angela LiniD· 1 shared Antonia L. CadelliD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alvin KamiliORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for MYCN-amplified high-risk neuroblastoma

Alvin Kamili, Brandon A. Hearn, Isabella Temelkoska, Joan Solomon, Madeleine S. Wheatley, Christina H.T. Bui, Caroline J. Atkinson, Leith-Justin Elhassadi, Sadia Qureshi, Jayne E. Murray, Roxanne Cadiz, Andrew J. Gifford, Lujing Cui, Lewis Crowley, Angela Lin, , Jamie I. Fletcher

This study identifies venetoclax-alisertib as a promising combination therapy for high-risk neuroblastoma, particularly effective in MYCN-amplified models, with improved survival and reduced toxicity.

bioRxiv · Sep 10, 2026 · PreprintCancer Biology

Inclusion of JNK-independent drugs within multi-agent chemotherapy improves response in relapsed high-risk neuroblastoma

Jeremy Z. R. Han, Monica Phimmachanh, Jordan F. Hastings, King Ho Leong, Boaz H. Ng, Jing Ni, Angela Fontaine-Titley, Antonia L. Cadell, Yolande E. I. O’Donnell, Misaki S. Clearwater, Alvin Kamili, Michelle Haber, Murray D. Norris, Paul Timpson, Toby N. Trahair, , David R. Croucher

The paper identifies JNK-independent drugs that, when combined with standard chemotherapy, improve response in relapsed high-risk neuroblastoma by exploiting differential apoptotic network utilization.

Science Advances · Nov 28, 2025Peer-reviewedCancer Biology